Sprint Bioscience AB (publ)

OM:SPRINT Stock Report

Market Cap: SEK 361.9m

Sprint Bioscience Management

Management criteria checks 4/4

Sprint Bioscience's CEO is Johan Emilsson, appointed in Oct 2023, has a tenure of 2.67 years. total yearly compensation is SEK2.22M, comprised of 75.5% salary and 24.5% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth SEK68.58K. The average tenure of the management team and the board of directors is 2.7 years and 6.4 years respectively.

Key information

Johan Emilsson

Chief executive officer

SEK 2.2m

Total compensation

CEO salary percentage75.54%
CEO tenure2.7yrs
CEO ownership0.02%
Management average tenure2.7yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Analysis Article • Jun 12

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Key Insights The projected fair value for Sprint Bioscience is kr0.77 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Feb 19

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Does the February share price for Sprint Bioscience AB (publ) ( STO:SPRINT ) reflect what it's really worth? Today, we...
Analysis Article • Nov 19

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO Compensation Analysis

How has Johan Emilsson's remuneration changed compared to Sprint Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

SEK 84m

Dec 31 2025n/an/a

SEK 92m

Sep 30 2025n/an/a

-SEK 26m

Jun 30 2025n/an/a

-SEK 22m

Mar 31 2025n/an/a

-SEK 21m

Dec 31 2024SEK 2mSEK 2m

-SEK 18m

Sep 30 2024n/an/a

-SEK 19m

Jun 30 2024n/an/a

SEK 15m

Mar 31 2024n/an/a

SEK 9m

Dec 31 2023SEK 2mSEK 420k

-SEK 438k

Compensation vs Market: Johan's total compensation ($USD234.75K) is about average for companies of similar size in the Swedish market ($USD311.70K).

Compensation vs Earnings: Johan's compensation has been consistent with company performance over the past year.

CEO

Johan Emilsson (42 yo)

2.7yrs
Tenure
SEK 2,224,000
Compensation

Mr. Johan Emilsson is Chief Executive Officer of Sprint Bioscience AB (publ) since October 01, 2023. He has broad experience in business development within the pharmaceutical industry and most recently fro...

Leadership Team

NamePositionTenureCompensationOwnership
Johan Emilsson
Chief Executive Officer2.7yrsSEK 2.22m0.019%
SEK 68.6k
Pär Nordlund
Founderno dataSEK 25.00kno data
Martin Andersson
Co-Founder17.4yrsno data0.26%
SEK 938.9k
Kenth Hallberg
Founder & Director of Structural Chemistryno datano datano data
Jenni Bjornulfson
Chief Financial Officerless than a yearno datano data
Anne-Marie Wenthzel
Chief Business Officerno datano data0.17%
SEK 610.7k
2.7yrs
Average Tenure
55yo
Average Age

Experienced Management: SPRINT's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Svein Mathisen
Independent Director6.4yrsSEK 165.00k0.043%
SEK 154.4k
Bjorn Sjostrand
Independent Chairman of the Board5.4yrsSEK 329.00k0.89%
SEK 3.2m
Lewis Cantley
Member of Scientific Advisory Boardno datano datano data
Rune Nordlander
Director16.4yrsSEK 165.00k9.99%
SEK 36.2m
Fredrik Lehmann
Independent Director7.1yrsSEK 165.00k0.047%
SEK 171.5k
Robert Devita
Member of Scientific Advisory Boardno datano datano data
Gunilla Enblad
Member of Scientific Advisory Boardno datano datano data
Karen From
Independent Director3.1yrsSEK 165.00kno data
6.4yrs
Average Tenure
64yo
Average Age

Experienced Board: SPRINT's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/07 23:00
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sprint Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siri LadowDanske Bank
Fredrik ThorRedeye